Table 2.

Conditions reported to be associated with OBI reactivation

Clinical conditions	Therapies
Hematological malignancies	ABVD
Non-Hodgkin lymphoma	BEAM
Hodgkin lymphoma	CHOP
Multiple myeloma	R-CHOP
Myelo-monoblastic acute leukemia	R-FND
Chronic lymphocytic leukemia	VAD
Hematopoietic stem cell transplantation	Temozolomide
Liver transplantation	Rituximab
Bone marrow transplantation	Adalimumab
Kidney transplantation	Tocilizumab
HIV infection	Abatacept
Rheumathoid arthritis	Infliximab
Glioblastoma	Etanercept
	Corticosteroids
	Methotrexate
	Leflunomide
	Bucillamin
	Valproic acid
	Romidepsin

ABVD adriamycin, bleomycin, vinblastine, dacarbazine; BEAM carmustine, etoposide, cytarabine, melphalan; CHOP cyclophosphamide, adriamycin/doxorubicin, vincristine, prednisone; R-CHOP rituximab and CHOP; R-FND rituximab, fludarabine, mitoxantrone, dexamethasone; VAD vincristine, adriamycine, dexamethasone